Moreover, we were able to demonstrate differential expression of CD24 in benign vs malignant tumours by immunohistochemistry; however, we could not definitively show significant differential expression of SPARCL1, as significant positive staining was observed in stromal cells from both the benign and malignant tumours. Here, SPARCL1 is linked to cancer.